May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreous Injections of a VEGF Receptor 2 Inhibitor Reduces Filopodia Length in Endothelial Tip Cells in the Rat Model of Oxygen Induced Retinopathy (OIR)
Author Affiliations & Notes
  • S. J. Budd
    UNC Chapel Hill, Chapel Hill, North Carolina
    Ophthalmology,
  • R. E. Cheney
    UNC Chapel Hill, Chapel Hill, North Carolina
    Cell and Molecular Physiology,
  • M. E. Hartnett
    UNC Chapel Hill, Chapel Hill, North Carolina
    Ophthalmology,
  • Footnotes
    Commercial Relationships  S.J. Budd, None; R.E. Cheney, None; M.E. Hartnett, None.
  • Footnotes
    Support  Research to Prevent Blindness NIH R01 EY015130
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 516. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. J. Budd, R. E. Cheney, M. E. Hartnett; Intravitreous Injections of a VEGF Receptor 2 Inhibitor Reduces Filopodia Length in Endothelial Tip Cells in the Rat Model of Oxygen Induced Retinopathy (OIR). Invest. Ophthalmol. Vis. Sci. 2008;49(13):516. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effect of inhibiting VEGF bioactivity with a neutralizing antibody to VEGF or a VEGF receptor 2 inhibitor on retinal endothelial tip cell filopodia in the 50/10 rat oxygen induced retinopathy (OIR) model.

Methods: : : Litters with 12-14 newborn pups and mothers were exposed to 24 hours of 50% oxygen followed by 10% oxygen repeated for seven cycles in an Oxycycler incubator. At postnatal day p12, the right eyes of pups in one litter were given intravitreous injections of either 1 µl of a neutralizing VEGF 164 antibody (50 ng/µl) or an IgG control. Similarly, pups of another litter were injected with SU5416 (10µM), a non-specific VEGF receptor 2 tyrosine kinase inhibitor or DMSO as a control. The doses of SU5416 and VEGF 164 antibody were chosen because we found their dose significantly reduced IVNV in the rat OIR model at p18. The left eyes remained non-injected. At p14, the retinas were removed, flat-mounted, and stained with Alexa Fluor 568 conjugated Grifonnia isolectin B4 (5 µg/ml). Flat-mounts were then imaged with a Leica SP2 laser scanning confocal microscope. Approximately 12-15 tip cells per retina were analyzed along the leading edge of vascular development. The number of filopodia in each tip cell was counted and their lengths were measured with ImageTool. The filopodia lengths for each tip cell was added together and expressed as a total length.

Results: : There was no significant difference in the number of filopodia per tip cell between eyes injected with the VEGF 164 antibody and the IgG control (ttest, n=5, p=.07) or between those injected with SU5416 and DMSO (ttest, n=5, p=.5). With eyes injected with SU5416, there was a significant 1.5 fold reduction in total filopodia length per tip cell compared to DMSO injected eyes (ttest, n=5, p=.002).

Conclusions: : Using a VEGF receptor 2 inhibitor, SU5416, filopodial length, but not number of filopodia in endothelial tip cells was reduced. Since the dose of SU5416 used caused reduction in IVNV, our data support that inhibiting the receptor tyrosine kinase activity of angiogenic receptors (e.g. VEGF R2) reduces angiogenesis by reducing the extension but not the number of filopodia in individual endothelial tip cells.

Keywords: retinopathy of prematurity • vascular endothelial growth factor • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×